Quick Answer
Green Tea Extract Cardiometabolic Meta-Analysis has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: 1 Metabolic syndrome (MetS) is a multifactorial disorder characterized by a cluster of metabolic and cardiovascular abnormalities, including central obesity, dyslipidemia, insulin resistance, and hypertension, which collectively increase the risk of suffering from metabolic diseases such as type 2 diabetes and cardiovascular diseases in the long term [].
Key Takeaways
- 011 Metabolic syndrome (MetS) is a multifactorial disorder characterized by a cluster of metabolic and cardiovascular abnormalities, including central obesity, dyslipidemia, insulin resistance, and hypertension, which collectively increase the risk of suffering from metabolic diseases such as type 2 diabetes and cardiovascular diseases in the long term []. [de la Fuente-Muñoz Mario (2026)]
- 02Impairment at any step, such as decreased IRS phosphorylation or PI3K/Akt activity, leads to defective glucose transport, reduced glycogen synthesis, increased lipolysis, and the development of insulin resistance []. [de la Fuente-Muñoz Mario (2026)]
- 036 7 8 9 10 11 One of the most important factors contributing to the development of insulin resistance is increased adiposity, and particularly visceral adiposity [], a condition that is present in most patients with MetS []. [de la Fuente-Muñoz Mario (2026)]
- 042 3 4 5 Central to the pathogenesis of MetS is insulin resistance, a condition characterized by the disruption of the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signaling pathway, a critical mediator of insulin’s metabolic actions in key metabolic tissues such as liver, muscle, and adipose tissue [,]. [de la Fuente-Muñoz Mario (2026)]
The current Migaku evidence database contains 2 reusable source documents for Green Tea Extract Cardiometabolic Meta-Analysis. This answer focuses on safety, limits, and clinician-discussion contexts.
- 1 Metabolic syndrome (MetS) is a multifactorial disorder characterized by a cluster of metabolic and cardiovascular abnormalities, including central obesity, dyslipidemia, insulin resistance, and hypertension, which collectively increase the risk of suffering from metabolic diseases such as type 2 diabetes and cardiovascular diseases in the long term []. [de la Fuente-Muñoz Mario (2026); evidence level 4]
- Impairment at any step, such as decreased IRS phosphorylation or PI3K/Akt activity, leads to defective glucose transport, reduced glycogen synthesis, increased lipolysis, and the development of insulin resistance []. [de la Fuente-Muñoz Mario (2026); evidence level 4]
- 6 7 8 9 10 11 One of the most important factors contributing to the development of insulin resistance is increased adiposity, and particularly visceral adiposity [], a condition that is present in most patients with MetS []. [de la Fuente-Muñoz Mario (2026); evidence level 4]
- 2 3 4 5 Central to the pathogenesis of MetS is insulin resistance, a condition characterized by the disruption of the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signaling pathway, a critical mediator of insulin’s metabolic actions in key metabolic tissues such as liver, muscle, and adipose tissue [,]. [de la Fuente-Muñoz Mario (2026); evidence level 4]
- Low-grade chronic inflammation and oxidative stress accompany obesity [,] and are at least partly attributed to gut barrier dysfunction that promotes endotoxemia-associated inflammation []. [Sasaki Geoffrey Y. (2022); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources
- Enhanced Effects of Complex Tea Extract and the Postbiotic BPL1 ® HT on Ameliorating the Cardiometabolic Alterations Associated with Metabolic Syndrome in Mice
- Catechin Bioavailability Following Consumption of a Green Tea Extract Confection Is Reduced in Obese Persons without Affecting Gut Microbial-Derived Valerolactones